The motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research

被引:4
|
作者
Wang, Zejuan [1 ]
Chen, Gang [1 ]
Liu, Xiaona [1 ]
Liu, Chen [2 ]
Song, Qingkun [3 ]
Wang, Jin [1 ]
机构
[1] Aerosp Ctr Hosp, Dept Clin Pharmacol, 15 Yuquan Rd, Beijing 100049, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Phase Clin Trial Ctr 1, 10 Tieyi Rd, Beijing 100038, Peoples R China
[3] Capital Med Univ, Beijing Shijitan Hosp, Dept Sci & Technol, 10 Tieyi Rd, Beijing 100038, Peoples R China
关键词
Healthy volunteers; Recruitment; Participation; Motivations; Barriers; Willingness; CLINICAL-RESEARCH; PARTICIPATE; WILLINGNESS; ATTITUDES; DECISION; MOTIVES; PAYMENT; TRIALS; RISKS;
D O I
10.1007/s00228-020-03040-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose To describe the motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research and to demonstrate the factors influencing their willingness to participate in subsequent trials. Methods Healthy subjects who participated in seven phase I trials at two centres were invited to participate in the cross-sectional survey at discharge by anonymously and voluntarily completing the self-administered questionnaire. Results From 442 subjects asked to complete the questionnaire, a response rate of 94.8% (419) was obtained, and 72.8% of the respondents had participated in a mean of 2.0 +/- 1.3 previous studies. Over 90% of the subjects indicated that the main motivations to participate trials were to help more people, to contribute to scientific research, and to obtain money. The top 5 barriers were time inconvenience, advertisement sources, potential risks associated with the drug, privacy, and the route of drug administration. Nearly half (49.6%) of the subjects were willing to participate in the next trial. The factors impacting the willingness of the subjects to participate in subsequent trials were gender, screening frequency, enrolment frequency, level of understanding of the research, two motivating factors (to make money and receive a free check-up), and ten barriers (e.g. risk, distance, living conditions, and trust). Conclusions The majority of healthy Chinese subjects were young, were less well educated, had low income levels, and had poor medical insurance coverage. Given the multiple sources of motivation and complex barriers to trial participation, investigators and recruitment staff should consider ethics aspects to guarantee volunteer safety and well-being.
引用
收藏
页码:557 / 568
页数:12
相关论文
共 50 条
  • [1] The motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research
    Zejuan Wang
    Gang Chen
    Xiaona Liu
    Chen Liu
    Qingkun Song
    Jin Wang
    European Journal of Clinical Pharmacology, 2021, 77 : 557 - 568
  • [2] Characteristics, Motivations, and Preferences of Healthy Volunteers in Phase I Clinical Trials in Sweden
    Rein-Hedin, Erik
    Schultzberg, Marten
    Sjoberg, Folke
    Huss, Fredrik
    JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2025,
  • [3] Healthy volunteers in US phase I clinical trials: Sociodemographic characteristics and participation over time
    Kalbaugh, Corey A.
    Kalbaugh, Julianne M.
    McManus, Lisa
    Fisher, Jill A.
    PLOS ONE, 2021, 16 (09):
  • [4] Motivations, enrollment decisions, and socio-demographic characteristics of healthy volunteers in phase 1 research
    Grady, Christine
    Bedarida, Gabriella
    Sinaii, Ninet
    Gregorio, Mark Anthony
    Emanuel, Ezekiel J.
    CLINICAL TRIALS, 2017, 14 (05) : 526 - 536
  • [5] Healthy volunteers in US phase I clinical trials: Sociodemographic characteristics and participation over time (vol 16, e0256994, 2021)
    Kalbaugh, C. A.
    Kalbaugh, J. M.
    McManus, L.
    Fisher, J. A.
    PLOS ONE, 2022, 17 (01):
  • [6] Phase I safety, tolerability, and pharmacokinetic studies of tetramethylpyrazine nitrone in healthy Chinese volunteers
    Zhao, Caiyun
    Lv, Yuan
    Cui, Hong
    Zhu, Yan
    Wei, Minji
    Xia, Yahong
    Tian, Jihong
    Ma, Yan
    Liu, Yan
    Zhang, Pu
    Wang, Xi
    Wu, Jing
    Wang, Yatai
    DRUG DEVELOPMENT RESEARCH, 2021, 82 (01) : 97 - 107
  • [7] A phase I study of monohydroxyethylrutoside in healthy volunteers
    Anja M. Willems
    Anne M. Bruynzeel
    Marc A. Kedde
    Cees J. van Groeningen
    Aalt Bast
    Wim J. van der Vijgh
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 678 - 684
  • [8] A phase I study of monohydroxyethylrutoside in healthy volunteers
    Willems, AM
    Bruynzeel, AM
    Kedde, MA
    van Groeningen, CJ
    Bast, A
    van der Vijgh, WJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 678 - 684
  • [9] A Study on the Characteristics of Healthy Volunteers who Participate in Phase I Clinical Trials in Korea
    Seo, Ji-Hye
    Kim, Ock-Joo
    Yoo, Sang-Ho
    Choi, Eun Kyung
    Park, Ji-Eun
    JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2022, 17 (1-2) : 193 - 212
  • [10] A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers
    Chen, Y.
    Jiang, J.
    Zhang, J.
    Tortorici, M. A.
    Pithavala, Y. K.
    Lu, L.
    Ni, G.
    Hu, P.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (11) : 679 - 687